Physician profile
Eric Dollar
NPI 1235578568
$4,623.52
in general payments reported to CMS, 2019-2025
14 companies · $367 in 2025
The $367 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $753 · 2020: $211 · 2021: $642 · 2022: $2,099 · 2023: $296 · 2024: $255 · 2025: $367.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $857 · Entertainment: $61.30.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $857.23 |
| Entertainment | $61.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Vision Care, INC. | $2,386.10 | 2019-2024 | |
| Alcon Vision LLC | $819.09 | 2021-2025 | Precision7, Total30, Precision 1 |
| Coopervision INC. | $360.11 | 2019-2024 | Clariti Contact Lens, Biofinity Contact Lens |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $358.01 | 2019-2021 | |
| Optos, INC. | $200.04 | 2020-2025 | Oct Ophthalmoscope, Panoramic Ophthalmoscope, Nfc-700 |
| Maculogix, INC. | $185.20 | 2019-2020 | |
| Visioneering Technologies, INC. | $100.39 | 2019 | |
| Shire North American Group INC | $73.02 | 2019 | |
| Allergan, INC. | $39.45 | 2021 | |
| Novartis Pharmaceuticals Corporation | $33.24 | 2021-2022 | |
| Biotissue Holdings INC. | $24.62 | 2021 | |
| Sight Sciences, INC. | $19.55 | 2019 | |
| Kala Pharmaceuticals, INC. | $12.58 | 2021 | |
| Bausch & Lomb Americas INC. | $12.12 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Dollar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.